Dimensional Fund Advisors LP Sells 20,341 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Dimensional Fund Advisors LP trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 499,096 shares of the biopharmaceutical company’s stock after selling 20,341 shares during the period. Dimensional Fund Advisors LP owned approximately 0.47% of Regeneron Pharmaceuticals worth $280,616,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $31,000. Caitlin John LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $34,000. Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $38,000. Finally, Berbice Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 in the last 90 days. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $759.82 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The business has a 50-day simple moving average of $770.81 and a two-hundred day simple moving average of $687.94. The company has a market capitalization of $80.33 billion, a P/E ratio of 18.28, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business posted $12.07 earnings per share. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research reports. HSBC began coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 price target on the stock. Scotiabank boosted their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a report on Monday, November 24th. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.